Immunome (IMNM) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Immunome (IMNM) is Neutral.

The composite score behind that read is +0.01, weighing +0.13 of bullish evidence against -0.21 bearish.

Immunome last closed at $19.55, +1.24% on the session.

Against the IVW growth benchmark the position is +0.44% over the forecast window.

The read is built from 15 underlying insights — 7 bullish and 8 bearish.

Agreement across those insights is 53%.

Immunome has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Immunome in the 18th percentile on return on equity, where 100 is best.

Immunome is classified under Health Care / Biotechnology, with a market capitalisation of $2.28B.

StockMap tracks Immunome as the 80th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Immunome ranks 89th of 381 in the group, against a group median of -0.08.